cessationtherapeutics

CHAPEL HILL, N.C.–(BUSINESS WIRE)–Cessation Therapeutics, Inc., (“Cessation”) a clinical-stage biotechnology company advancing biologics that target substances of abuse, announced today that the U.S. Food and Drug Administration (FDA) has authorized the company to initiate a clinical trial in the U.S. for CSX-1004, a monoclonal antibody designed specifically to prevent fentanyl overdose.

As a Navy admiral, I helped lead one of the most powerful militaries in the world. Today, our nation is fighting an urgent war right here at home. The opioid crisis in America has now become a fentanyl crisis. A synthetic opioid that is at least 50 times more potent than morphine, fentanyl is both exceedingly …

Tens of Thousands of Americans are Dying Every Year from Fentanyl Overdose It’s time to fight fentanyl like the foe that it is Read More »

CHAPEL HILL, N.C.–(BUSINESS WIRE)–Cessation Therapeutics (“Cessation”), an early-stage biotechnology company focused on the development of novel immunobiologics for preventing and treating fentanyl overdose, today announced a new study demonstrating that its pioneering anti-fentanyl monoclonal antibody treatment, CSX-1004, may provide robust and durable protection from life-threatening respiratory depression caused by high doses of fentanyl.